For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
How it works
Thioguanine nucleotides are incorporated into both the DNA and the RNA by phosphodiester linkages and inhibits tumor by inhibition of de novo purine synthesis; inhibition of purine nucleotide incorporation into the DNA and RNa blockade the utilization and synthesis of the purine nucleotides.
Common side effects
Nausea, Rash, Anemia, Dermatitis, Diarrhoea, Increased uric acid level in blood, Jaundice, Stomatitis, Loss of appetite, Reduced blood platelets, Vomiting
- 1 variant(s)